Lack of new antiepileptic drugs, less than 30% of domestic brands in 5 billion market

Epilepsy is one of the three major diseases of human central nervous system, and also one of the oldest and most typical diseases in history The incidence rate is even higher than that of Alzheimer's In recent years, with the growth of immune vaccine and antiviral drug treatment market, infectious diseases have been effectively controlled; relatively speaking, the market of nervous system and psychiatric drugs has shown a growing trend year by year According to the World Health Organization (who) report, the global active epilepsy patients account for about 8.2% of the world's total population, with a total of more than 50 million people, adding 2 million epilepsy patients every year The incidence rate of China's epilepsy is relatively low, the overall prevalence rate is about 7%, which is close to 7.2% of the incidence rate in developing countries Under the influence of a large population base, nearly 10 million epileptic patients need to get reasonable treatment, of which more than 6 million are epileptic patients, and the number of newly increased epileptic patients still reaches more than 400000 every year Strengthening the development of antiepileptic drugs is still one of the important topics at home and abroad none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; font-size: 17px; letter-spacing: 0.544px; line-height: 25.6px; color: rgb(62, 62, 62); border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; Word wrap: break word! Im portant; "> the popularization of nervous system drugs According to the data of minenet, the State Food and drug administration has published four batches of generic drug consistency evaluation lists By May 25, 2018, 41 product specifications have passed the consistency evaluation Five nervous system drugs, including paroxetine and risperidone, the antidepressant of Zhejiang Huahai Pharmaceutical Co., Ltd., escitalopram oxalate, the antidepressant of Sichuan Kelun Pharmaceutical Co., Ltd and Hunan Dongting Pharmaceutical Co., Ltd., olanzapine, the antidepressant of Jiangsu Haosen Pharmaceutical Co., Ltd., and levetiracetam, the antidepressant of Zhejiang Jingxin Pharmaceutical Co., Ltd., have passed the consistency evaluation In particular, levetiracetam tablets are used for the treatment of partial seizures in adults and children over 4 years old, and play an important role in clinical treatment The 2017 International League Against Epilepsy (ILAE) launched a new epilepsy and epilepsy classification system, which has been 35 years since the release of the previous classic classification system, and is a major innovation in the field of epilepsy In February 2017, the Hong Kong Epilepsy Society updated the guidelines for the use of antiepileptic drugs It provides guidelines for the use of levetiracetam, oxcarbazepine, lacolamide, pregabalin and EDC membrane coated tablets, and emphasizes the important role of the new AEDs in clinical
none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; font-size: 17px; letter-spacing: 0.544px; line-height: 25.6px; color: rgb(62, 62, 62); border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: Break word! Im assistant; "> the latest anti epilepsy data of public hospitals in key cities 2017 national medical insurance drug catalog contains 13 anti epilepsy (EPD) drugs It includes traditional AEDs drugs and five new AEDs drugs, including levolacetam (Lev), OXC, gabapentin (GBP), lamotrigine (LTG) and topiramate (TPM), etc According to the data of minenet, in 2017, the market of antiepileptic drugs in more than 400 public hospitals in 16 cities in China exceeded 800 million yuan, an increase of 8.33% over the previous year In 2017, the sales volume of public medical institutions and drugstores' retail terminals for antiepileptic drugs reached 4.96 billion yuan, approaching the market scale of 5 billion yuan The market of antiepileptic drugs in top 3 is in full swing, among which sodium valproate accounts for 30.83%, levetiracetam 27.84% and oxcarbazepine 14.93% The top 10 varieties are valproate, levetiracetam, oxcarbazepine, lamotrigine, gabapentin, pregabalin, topiramate, magnesium valproate, carbamazepine and clonazepam
none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; font-size: 17px; letter-spacing: 0.544px; line-height: 25.6px; color: rgb(62, 62, 62); border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: Break word! Im assistant; "> valproate is a fatty acid derivative drug developed by Abbott In 2001, Sanofi from France was approved to enter the Chinese market under the trade name of depakine CFDA has approved the listing of 15 domestic sodium valproate Sodium valproate has been listed in the national medical insurance drug catalog As a traditional antiepileptic drug, valproate has been used for a long time Doctors are familiar with its indications and adverse reactions, and it has the advantage of low price Valproate is effective in the treatment of various types of epilepsy, including complex partial seizures, generalized tonic clonic seizures, myoclonic seizures and status epilepticus According to the data of minenet, in 2017, more than 400 public hospitals in 16 cities in China used 247 million yuan of valproate, an increase of 11.32% over the previous year Sanofi accounted for 64.91%, Shenyang Xinma for 16.86%, Sichuan kered for 16.30% and others only accounted for 1.93% Among them, 61.97% were powder injection, 31.20% were tablets and 6.83% were solution
none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; font-size: 17px; letter-spacing: 0.544px; line-height: 25.6px; color: rgb(62, 62, 62); border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; Word wrap: break word! Im portant; "> levetiracetam is pressing for the first place Levetiracetam was developed by UCB company of Belgium It entered the Chinese market in 2006, and its trade name is Pulan The formulation of levetiracetam on the market in the world includes tablet, sustained-release tablet, oral solution and injection Only tablet and oral solution are introduced in China After the expiration of the patent of levetiracetam, four domestic enterprises have been approved for production, which is a new drug in the 2017 national medical insurance drug catalog Levetiracetam is recognized as the gold standard drug for the treatment of epilepsy in the world In 2017, the market of levetiracetam in UCB in Belgium reached 778 million US dollars, an increase of 8.10% over the previous year Levetiracetam has maintained a rapid clinical growth rate in China According to the data of mienei.com, in 2017, more than 400 public hospitals in 16 cities in China used 23 million yuan of levetiracetam, an increase of 11.40% over the previous year UCB company of Belgium, the top 3 manufacturer, accounts for 99.27%, Jingxin Pharmaceutical Co., Ltd of Zhejiang Province accounts for 0.47%, and shenghuaxi Pharmaceutical Co., Ltd of Chongqing Province accounts for 0.25% According to the previous data from the intranet database, in 2016, the sales of zuelacetan preparations in China reached 833 million yuan Now, after the consistency evaluation, the new zuelacetan tablets in Beijing, Zhejiang Province will drive the terminal consumption, and it is estimated that the scale will exceed 1 billion yuan in 2018
none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; font-size: 17px; letter-spacing: 0.544px; line-height: 25.6px; color: rgb(62, 62, 62); border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: Break word! Im portant; "> oxcarbazepine is a drug approved by FDA to be listed in Novartis in 2000 Its trade name is Trileptal In 2015, the global market reached 176 million US dollars In 2004, it entered the Chinese market and became a famous qulai In China, it is produced and listed by Beijing 4th Ring Road and humanwell Pharmaceutical Co., Ltd., forming a tripartite confrontation Since 2012, the sales of oxcarbazepine has been on a steady upward trend since it ranked third in the field of antiepileptic drugs According to the data of minenet, in 2017, over 400 public hospitals in 16 cities in China used 120 million yuan of oxcarbazepine, an increase of 3.29% over the previous year Qulai of top 3 brand Novartis accounted for 88.34%, ren'ao of Beijing Fourth Ring Road accounted for 8.76%, and Wanyi of humanwell pharmaceutical accounted for 2.90%
none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; font-size: 17px; letter-spacing: 0.544px; line-height: 25.6px; color: rgb(62, 62, 62); border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; Word wrap: break word! Im portant; "> the development of lamotrigine is disadvantageous Lamotrigine is a drug of GlaxoSmithKline, which has the activity of resisting folate and is a kind of triaazabenzene compound It is a commodity of minglitong China has approved the listing of Sanjin Group Hunan Sanjin pharmaceutical The mechanism of lamotrigine can block the sodium channel, stabilize the cell membrane, prevent the release of glutamate and other excitatory neurotransmitters, so as to play an anti epileptic role The drug is very effective for partial seizures and secondary generalized seizures, but less effective for primary generalized seizures In recent years, the growth of lamotrigine in China is slow Influenced by GSK operation, lamotrigine shows a downward trend, while the academic promotion effect of domestic manufacturers is not significant, leading to the overall market ups and downs According to the data of mienei.com, in 2017, more than 400 public hospitals in 16 cities in China used 5.51 million yuan of lamotrigine, a year-on-year decrease of 3.46% There are only two sales in China, among which libitong of GlaxoSmithKline company accounts for 94.07% and ambroxine of Hunan Sanjin pharmaceutical of Sanjin group accounts for 5.93%
none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; font-size: 17px; letter-spacing: 0.544px; line-height: 25.6px; color: rgb(62, 62, 62); border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; Word wrap: break word! Im portant; "> is gabapentin a rising star? Gabapentin is a drug developed by Pfizer It can be used alone for the treatment of general epilepsy, but also as a superimposed treatment of refractory epilepsy Its trade name is Neurontin Pfizer's gabapentin peaked at $2.8 billion at the beginning of the world economy With the expiration of patents and the listing of generic drugs, the global Neurontin market in 2016 was still US $182 million In 2003, gabapentin was successfully developed in China CFDA approved the listing of Jiangsu Hengrui Pharmaceutical Co., Ltd., Jiangsu Enhua Pharmaceutical Group and Hainan selec pharmaceutical preparations Compared with the similar products currently used, gabapentin has the advantages of fast oral absorption, good tolerance, small side effects, good therapeutic effect, no metabolism in the body, no binding with plasma protein, no induction of liver enzyme, it can pass through the blood-brain barrier of human brain, and the possibility of interaction with other antiepileptic drugs is very low It is especially prominent as the superimposed drug of intractable epilepsy Out According to the data of mierne.com, in 2017, over 400 public hospitals in 16 cities in China used gabapentin for 35.13 million yuan, an increase of 7.9% over the previous year Jiangsu Enhua Pharmaceutical Co., Ltd accounts for 53.97% of the total brands, Jiangsu Hengrui Pharmaceutical Co., Ltd 32.25% of the total brands, and Hainan selec